AVMA-endorsed xylazine legislation reintroduced in CongressFebruary 20, 2025The AVMA reintroduced the Combating Illicit Xylazine Act in both the House and Senate. The legislation is reported to provide the U.S. Drug Enforcement Administration (DEA) with tools to help address the illicit drug by scheduling xylazine as a Schedule III drug, ensure common veterinary uses of the drug remain legal, help maintain the availability of the drug on the market for veterinarians, and allow the DEA to track the legitimate supply.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
